Stockscreener 앱 받기
16.37
1.17%
0.19
전일 마감가:
$16.18
열려 있는:
$16.15
하루 거래량:
1.36M
Relative Volume:
1.04
시가총액:
$2.72B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
-17.79
EPS:
-0.92
순현금흐름:
$80.53M
1주 성능:
-2.39%
1개월 성능:
+12.74%
6개월 성능:
+3.48%
1년 성능:
-25.56%
1일 변동 폭
$16.01
$16.69
1주일 범위
$15.66
$17.17
52주 변동 폭
$14.15
$32.59
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ACAD | 16.37 | 2.72B | 890.53M | 30.57M | 80.53M | -0.92 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Principal Financial Group Inc. Acquires 52,340 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - The Bakersfield Californian
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
When (ACAD) Moves Investors should Listen - Stock Traders Daily
Acadia Pharmaceuticals announces executive shakeup - Investing.com
Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause - MarketWatch
Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure - TipRanks
Acadia Pharmaceuticals announces executive shakeup By Investing.com - Investing.com UK
Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause - StreetInsider.com
Acadia Pharma ticks lower amid Deutsche Bank downgrade after surge on patent win - MSN
Leerink Partnrs Issues Pessimistic Outlook for ACAD Earnings - MarketBeat
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth - MSN
Acadia Pharmaceuticals CFO sells shares worth $172,453 - Investing.com India
Acadia Pharmaceuticals CFO sells shares worth $172,453 By Investing.com - Investing.com Canada
Acadia Pharmaceuticals' COO sells $173,630 in stock By Investing.com - Investing.com Canada
FY2024 Earnings Estimate for ACAD Issued By Leerink Partnrs - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat
Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com
Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance
US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha
What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat
FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN
ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq
Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey
Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St
ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Quarterly 10-Q Report - Quartzy
ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results - MarketBeat
Acadia Pharmaceuticals participates in a conference call with JPMorgan - TipRanks
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given Buy Rating at HC Wainwright - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Acadia Pharma Q3 2024 Earnings Preview - MSN
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highligh - GuruFocus.com
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Acadia: Q3 Earnings Snapshot - Houston Chronicle
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - BioSpace
Acadia Pharmaceuticals Sees Revenue Growth and Strategic Advances - TipRanks
Acadia Pharmaceuticals reports Q3 EPS , consensus 14c - TipRanks
ACADIA Pharmaceuticals Q3 2024 Earnings: EPS of $0.20 Beats Esti - GuruFocus.com
Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - MedCity News
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):